SurModics, Inc. (SRDX) - Bull of the Day

By Zacks.com,  May 25, 2012, 01:00:01 AM EDT

SurModics, Inc. ( SRDX ) second quarter fiscal 2012 adjusted earnings of $0.14 per share beat the Zacks Consensus Estimate by $0.02. The company also topped the Zacks Consensus revenue estimate. Given SurModic's strong product portfolio, we expect it to achieve fiscal 2012 guidance of $47-$51 million.

We are also pleased with the sale of the SurModics Pharmaceuticals unit, as this has allowed the company to focus on its core businesses. Performance of the company has been steadily improving since a disappointing fiscal 2010. The company took a number of corrective measures, including a change at its helm.

We believe SurModics will continue performing well going forward, and have raised our earnings estimates for fiscal 2012 and 2013. In view of these positives, we upgrade SurModics to Outperform. Our target price is $17.00.
 
SURMODICS (SRDX): Free Stock Analysis Report
 
To read this article on Zacks.com click here.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.


This article appears in: Investing, Stocks

Referenced Stocks: SRDX



Latest News Video

Anti-Islamist English Defense League Takes to Streets of Newcastle
Anti-Islamist English Defense Leagu...
Missouri Train Crash Collapses Overpass, Injures 7
Missouri Train Crash Collapses Over...


Sign-in
Existing NASDAQ.com member? Log in here.

By signing into to the site using any of the third-party services above, you agree to NASDAQ.com's Terms of Use.

From Our Trusted News Source





Most Active by Volume:

Company Last Sale Change Net / %
BAC $ 13.24 0.03  0.23%
FB $ 24.32 0.74  2.95%
SIRI $ 3.58 0.04  0.99%
GE $ 23.53 0.13  0.55%
PFE $ 29.04 0.07  0.24%
MSFT $ 34.27 0.12  0.35%
INTC $ 23.93 0.12  0.50%
P $ 16.43 0.73  4.25%